Skip to search formSkip to main contentSkip to account menu

riociguat

Known as: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate, Riociguatum 
National Institutes of Health

Related topics

Related topics

8 relations

Narrower (1)

Adempas
Guanylate Cyclase Stimulators [MoA]riociguat 0.5 MG Oral Tabletriociguat 1 MG Oral Tablet [Adempas]riociguat 1.5 MG Oral Tablet [Adempas]

Broader (2)

PyrazolesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Mechanism of thromboxane receptor-induced vasoconstriction in human saphenous vein.
2019
2019
In vitro–in vivo correlation of the drug–drug interaction potential of antiretroviral HIV treatment regimens on CYP1A1 substrate riociguat
ABSTRACT Objectives: Riociguat is a soluble guanylate cyclase stimulator licensed for the treatment of pulmonary arterial… 
2017
2017
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
Patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-PAH-CTD) such as systemic sclerosis… 
2016
2016
Absorption of Riociguat (BAY 63-2521): Bioavailability, Food Effects, and Dose Proportionality
Riociguat (BAY 63-2521) is the first member of a novel class of compounds, the soluble guanylate cyclase (sGC) stimulators… 
2016
2016
Population Pharmacokinetics and the Pharmacokinetic/Pharmacodynamic Relationship of Riociguat in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
This analysis aimed to characterize the pharmacokinetics (PK) and PK/pharmacodynamic (PK/PD) relationship of riociguat and its… 
2016
2016
Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
2016
2016
Population Pharmacokinetics of Single-Dose Riociguat in Patients with Renal or Hepatic Impairment
This population pharmacokinetics (PK) analysis characterized the PK of the oral soluble guanylate cyclase stimulator riociguat in… 
2014
2014
Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
Review
2011
Review
2011
Treating pulmonary arterial hypertension: current treatments and future prospects
Pulmonary arterial hypertension (PAH) consists of a group of heterogeneous but distinct disorders characterized by complex… 
Review
2006
Review
2006
Pulmonary Arterial Hypertension
The treatment of pediatric pulmonary arterial hypertension (PAH) is challenging due to the serious nature of the disease, its… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)